About JDS Therapeutics
JDS Therapeutics is a company based in Purchase (United States) founded in 2011 was acquired by Noven in July 2007. JDS Therapeutics has raised $16 million across 1 funding round from investors including Noven and 1315 Capital. The company has 75 employees.
- Headquarter Purchase, United States
- Employees 75
- Email••••••••
- Website jdstherapeutics.com
- Social LinkedIn
- Acquired by Noven (Jul 2007)
Funding Insights of JDS Therapeutics
JDS Therapeutics has successfully raised a total of $16M through 1 strategic funding round. The most recent funding activity was a Series B round of $16 million completed in October 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $16M
- Total Rounds 1
- Last Round Series B — $16M
- First Round $16M
(Oct 2015)
- Investors Count 1
All 1 funding rounds of JDS Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2015 | $16M | Series B | – | – |
2 investors in total: 2 institutional.
Investors in JDS Therapeutics
JDS Therapeutics has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Noven and 1315 Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Expansion and growth capital is provided by 1315 Capital to healthcare companies. | – | 1315capital.com | Philadelphia, United States | |
A specialty pharmaceutical company focused on transdermal drug delivery. | 1987 | noven.com | Miami, United States |
Investor details for JDS Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of JDS Therapeutics
1 people are tracked at JDS Therapeutics (1 in leadership); the tracked headcount is 75.
| Name | Role | Group |
|---|---|---|
Michael Satow | Co-founder And Strategic Advisor | Leadership |
Complete people profiles for JDS Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of JDS Therapeutics
3 dated milestones of JDS Therapeutics across 8 years, from founding to its latest funding, stage changes and deals.
- Exit Acquired by Noven.
- Founded JDS Therapeutics is founded.
- Funding First funding round of $16.0M.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about JDS Therapeutics
JDS Therapeutics was founded in 2011 and raised its 1st funding round 4 years after it was founded.
JDS Therapeutics is headquartered in Purchase, United States. It is registered at Purchase, New York, United States.
JDS Therapeutics is a funded company, having raised a total of $16M across 1 funding round to date. The company's 1st funding round was a Series B of $16M, raised on Oct 2015.
JDS Therapeutics has 75 employees.
Founded in 2011 and based in Purchase, United States, hormone-free products for menopause symptoms are developed by the company. Specific issues such as vaginal dryness, hot flashes, vaginal odor, mood swings, and reduced sexual satisfaction are targeted. Clinically tested natural ingredients are incorporated into proprietary formulations. Rigorous testing is conducted to verify safety and efficacy, with recommendations from gynecologists. Operations focus on precision-based solutions within the womens health sector.
JDS Therapeutics has 2 investors. Key investors include Noven, and 1315 Capital.
Yes. JDS Therapeutics was acquired by Noven in July 2007.